[go: up one dir, main page]

ES2191356T3 - Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos. - Google Patents

Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos.

Info

Publication number
ES2191356T3
ES2191356T3 ES98957270T ES98957270T ES2191356T3 ES 2191356 T3 ES2191356 T3 ES 2191356T3 ES 98957270 T ES98957270 T ES 98957270T ES 98957270 T ES98957270 T ES 98957270T ES 2191356 T3 ES2191356 T3 ES 2191356T3
Authority
ES
Spain
Prior art keywords
alkyl
secretion
inhibition
procedures
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98957270T
Other languages
English (en)
Inventor
Kosrat Amin
Mikael Dahlstrom
Peter Nordberg
Ingemar Starke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2191356T3 publication Critical patent/ES2191356T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la Fórmula I **(Fórmula)** o una de sus sales farmacéuticamente aceptables, en que R1 es alquilo C1-C6; R2 es alquilo C1-C6; R3 es H o halógeno; y **(Fórmula)** es un heterociclo sustituido seleccionado entre **(Fórmula)** en que R4 es H, CH3, CH2OH o CH2CN; R5 es H o alquilo C1-C6; R6 es H, alquilo C1-C6, arilo, arilalquilo que contiene 1-2 átomos de carbono en la parte de alquilo, alquenilo C2-C6, halo(alquenilo C2-C6), alquinilo C2-C6, cicloalquilo C3-C7 o halo(alquilo C1-C6); R7 es H, halógeno, alquilo C1-C6, alquiltio C1-C6 o tiociano; n es 0 ó 1; y X es NH o O.
ES98957270T 1997-11-28 1998-11-18 Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos. Expired - Lifetime ES2191356T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704404A SE9704404D0 (sv) 1997-11-28 1997-11-28 New compounds

Publications (1)

Publication Number Publication Date
ES2191356T3 true ES2191356T3 (es) 2003-09-01

Family

ID=20409181

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98957270T Expired - Lifetime ES2191356T3 (es) 1997-11-28 1998-11-18 Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos.

Country Status (32)

Country Link
US (1) US6518270B1 (es)
EP (1) EP1042324B1 (es)
JP (1) JP2001525322A (es)
KR (1) KR20010032559A (es)
CN (1) CN1142933C (es)
AR (1) AR016972A1 (es)
AT (1) ATE233263T1 (es)
AU (1) AU752187C (es)
BR (1) BR9814755A (es)
CA (1) CA2311798A1 (es)
CZ (1) CZ292349B6 (es)
DE (1) DE69811735T2 (es)
DK (1) DK1042324T3 (es)
EE (1) EE04060B1 (es)
ES (1) ES2191356T3 (es)
HU (1) HUP0100601A3 (es)
ID (1) ID24730A (es)
IL (1) IL136145A0 (es)
IS (1) IS5486A (es)
MY (1) MY121032A (es)
NO (1) NO315704B1 (es)
NZ (1) NZ504355A (es)
PL (1) PL340920A1 (es)
PT (1) PT1042324E (es)
RU (1) RU2241000C2 (es)
SE (1) SE9704404D0 (es)
SK (1) SK283904B6 (es)
TR (1) TR200001530T2 (es)
TW (1) TW515798B (es)
UA (1) UA70932C2 (es)
WO (1) WO1999028322A1 (es)
ZA (1) ZA9810468B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
AU2002367773A1 (en) * 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP2003119140A (ja) * 2001-08-08 2003-04-23 Sankyo Co Ltd ピロロピリダジン化合物を含有する医薬
IL164703A0 (en) 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
WO2004029057A1 (ja) * 2002-09-25 2004-04-08 Sankyo Company, Limited 内臓痛の治療または予防のための医薬組成物
WO2004029058A1 (ja) * 2002-09-25 2004-04-08 Sankyo Company, Limited 血中ガストリン濃度上昇の抑制のための医薬組成物
SI1575951T1 (sl) 2002-12-06 2014-10-30 Debiopharm International Sa Forum "Apres-Demain" Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
AR043002A1 (es) * 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
ATE409485T1 (de) * 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
CA2544325A1 (en) 2003-11-03 2005-05-12 Astrazeneca Ab Imidazo [1,2-a] pyridine derivatives for the treatment of silent gastro-esophageal reflux
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
ATE527258T1 (de) * 2004-07-28 2011-10-15 Takeda Pharmaceutical Pyrroloä2,3-cüpyridinverbindung, verfahren zu deren herstellung und anwendung
EP1776361A1 (en) * 2004-08-02 2007-04-25 Altana Pharma AG 5-substituted 1h-pyrroloý3,2-b¨pyridines
EP1784402B1 (en) * 2004-09-03 2011-08-03 Yuhan Corporation PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
JP4989477B2 (ja) * 2004-09-03 2012-08-01 ユーハン・コーポレイション ピロロ［３，２−ｃ］ピリジン誘導体及びその製造方法
MX2007002219A (es) * 2004-09-03 2007-05-04 Yuhan Corp Derivados de pirrolo [3,2-b ] piridina y procesos para su preparacion.
KR100958829B1 (ko) * 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
AR061229A1 (es) 2006-06-06 2008-08-13 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
EP3255045A1 (en) * 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
KR101745732B1 (ko) 2008-12-08 2017-06-12 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
MX2011006094A (es) 2008-12-08 2011-11-29 Gilead Connecticut Inc Inhibidores de imidazopirazina syk.
BR112012022943A2 (pt) 2010-03-11 2018-06-05 Gilead Connecticut Inc inibidores de syk de imidazopiridnas
MY170437A (en) 2012-06-19 2019-07-31 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
SG11201603050TA (en) 2013-12-04 2016-05-30 Gilead Sciences Inc Methods for treating cancers
GB201321738D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
MX2017000610A (es) 2014-07-14 2017-04-27 Gilead Sciences Inc Metodos combinados para tratar canceres.
PL3419628T3 (pl) 2016-02-26 2021-05-31 Debiopharm International Sa Lek do leczenia zakażeń stopy cukrzycowej
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
HRP20230437T1 (hr) 2019-02-14 2023-07-07 Debiopharm International S.A. Formulacija afabicina, postupak izrade iste
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507294A (en) 1982-03-08 1985-03-26 Schering Corp. Imidazo[1,2-a]pyrazines
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
IL97931A0 (en) 1990-04-27 1992-06-21 Byk Gulden Lomberg Chem Fab Pyridazine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
AU8712191A (en) * 1990-10-15 1992-05-20 Byk Gulden Lomberg Chemische Fabrik Gmbh New diazines
AU2870492A (en) * 1991-10-25 1993-05-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrrolo-pyridazines with gastro-intestinal protective action
DE69529056T2 (de) 1994-01-19 2003-11-13 Sankyo Co., Ltd. Pyrrolopyridazin-derivate
SE9602286D0 (sv) 1996-06-10 1996-06-10 Astra Ab New compounds
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds

Also Published As

Publication number Publication date
TR200001530T2 (tr) 2000-11-21
JP2001525322A (ja) 2001-12-11
EE04060B1 (et) 2003-06-16
DE69811735T2 (de) 2003-12-18
BR9814755A (pt) 2000-10-03
AU752187C (en) 2003-09-18
KR20010032559A (ko) 2001-04-25
NO315704B1 (no) 2003-10-13
ZA9810468B (en) 1999-05-21
MY121032A (en) 2005-12-30
NO20002721L (no) 2000-07-28
NZ504355A (en) 2001-12-21
AU1356599A (en) 1999-06-16
HUP0100601A3 (en) 2002-10-28
DE69811735D1 (de) 2003-04-03
IS5486A (is) 2000-05-10
AR016972A1 (es) 2001-08-01
HK1030216A1 (en) 2001-04-27
SK283904B6 (sk) 2004-04-06
AU752187B2 (en) 2002-09-12
SE9704404D0 (sv) 1997-11-28
UA70932C2 (uk) 2004-11-15
ID24730A (id) 2000-08-03
NO20002721D0 (no) 2000-05-26
SK6742000A3 (en) 2001-03-12
IL136145A0 (en) 2001-05-20
CZ292349B6 (cs) 2003-09-17
RU2241000C2 (ru) 2004-11-27
EE200000315A (et) 2001-10-15
CN1284078A (zh) 2001-02-14
EP1042324B1 (en) 2003-02-26
DK1042324T3 (da) 2003-05-05
TW515798B (en) 2003-01-01
PT1042324E (pt) 2003-06-30
CZ20001947A3 (cs) 2000-11-15
WO1999028322A1 (en) 1999-06-10
ATE233263T1 (de) 2003-03-15
EP1042324A1 (en) 2000-10-11
US6518270B1 (en) 2003-02-11
CN1142933C (zh) 2004-03-24
CA2311798A1 (en) 1999-06-10
PL340920A1 (en) 2001-03-12
HUP0100601A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
ES2191356T3 (es) Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos.
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
AU7503087A (en) Amide derivatives
ZA200108124B (en) Pharmaceutical compounds.
HUP0102099A2 (hu) Szubsztituált 2-oxo-alkánsav-[2-(indol-3-il)-etil]-amid-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL134894A (en) 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them
MY125562A (en) Hexahydro-pyrido (4,3-b) indole derivatives as antipsychotic drugs
EP1034783A4 (en) AMIDE DERIVATIVES
YU73202A (sh) Novi proces za sintezu n-/(s)-1-karboksibutil/-(s)- alaninskog estra i primena u sintezi perindoprila
PL335012A1 (en) Novel derivatives of indan-1-ole, method of obtaining and composition containing them
NO964216D0 (no) Ester- og karbamatderivater av azoloner som er kraftige midler mot Helicobacter
DK0412015T3 (da) Hidtil ukendte N-(23-vincristinoyl)- og N-(5-noranhydro-23-vinblastinoyl)-1-aminomethylphosphon- syrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DE69917236D1 (de) Heterocyclische anthracyclinonderivate
AR004401A1 (es) Derivados de la tirosina, procedimiento para prepararlos y preparaciones farmaceuticas que los contienen.
AP2002002707A0 (en) 4, 5-Dihydro-Thiazo-2-Ylamine Derivatives and their Use as NO-Synthase Inhibitors.